JANX
NASDAQJanux Therapeutics Inc.
Price$14.90+0.25 (+1.74%)
01:30 PM07:45 PM
News · 26 weeks48+43%
2025-12-282026-06-21
Mix2790d
- Insider9(33%)
- Other8(30%)
- SEC Filings7(26%)
- Analyst2(7%)
- Leadership1(4%)
Latest news
25 items- SECJanux Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Janux Therapeutics, Inc. (0001817713) (Filer)
- INSIDERDirector Ra Capital Management, L.P. was granted 5,500 shares (SEC Form 4)4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
- INSIDERDirector Simson Jake was granted 5,500 shares (SEC Form 4)4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
- INSIDERDirector Hernday Natasha was granted 5,500 shares, increasing direct ownership by 55% to 15,481 units (SEC Form 4)4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
- INSIDERDirector Kung Winston was granted 5,500 shares, increasing direct ownership by 88% to 11,750 units (SEC Form 4)4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
- INSIDERDirector Capps Vickie L was granted 5,500 shares, increasing direct ownership by 7% to 79,598 units (SEC Form 4)4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
- INSIDERDirector Barrett Ronald W was granted 5,500 shares, increasing direct ownership by 88% to 11,750 units (SEC Form 4)4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
- INSIDERDirector Dobmeier Eric was granted 5,500 shares, increasing direct ownership by 55% to 15,481 units (SEC Form 4)4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
- SECJanux Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Janux Therapeutics, Inc. (0001817713) (Filer)
- INSIDERChief Corp. & Bus. Dev. Ofcr Doyle Janeen Noel sold $56,944 worth of shares (4,059 units at $14.03), decreasing direct ownership by 5% to 75,941 units (SEC Form 4) to satisfy tax liability4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.SCHEDULE 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
- INSIDERVice President, Accounting Dobek Maria sold $28,878 worth of shares (2,038 units at $14.17), decreasing direct ownership by 6% to 32,270 units (SEC Form 4)4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.SCHEDULE 13G - Janux Therapeutics, Inc. (0001817713) (Subject)
- SECSEC Form 10-Q filed by Janux Therapeutics Inc.10-Q - Janux Therapeutics, Inc. (0001817713) (Filer)
- SECJanux Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Janux Therapeutics, Inc. (0001817713) (Filer)
- PRJanux Therapeutics Reports First Quarter 2026 Financial Results and Business HighlightsJANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate JANX011 Phase 1 study ongoing in healthy volunteers Discontinued development of JANX008 following completion of Phase 1a Achieved development candidate nomination under Bristol Myers Squibb collaboration, triggering milestone payment Strong cash position supporting continued pipeline execution Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results fo
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.SCHEDULE 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
- SECSEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.SCHEDULE 13G - Janux Therapeutics, Inc. (0001817713) (Subject)
- SECSEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.SCHEDULE 13G - Janux Therapeutics, Inc. (0001817713) (Subject)
- SECJanux Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Janux Therapeutics, Inc. (0001817713) (Filer)
- SECSEC Form DEFA14A filed by Janux Therapeutics Inc.DEFA14A - Janux Therapeutics, Inc. (0001817713) (Filer)
- SECSEC Form DEF 14A filed by Janux Therapeutics Inc.DEF 14A - Janux Therapeutics, Inc. (0001817713) (Filer)
- PRJanux Therapeutics Announces Discontinuation of JANX008 Clinical DevelopmentJanux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further clinical development of JANX008, its EGFR-targeted Tumor Activated T Cell Engager (TRACTr) program. Following completion of the Phase 1a portion of the study, which included dose escalation and expansion cohorts across multiple solid tumor indications, and an internal review of the data, the Company has determined to prioritize development resources toward other pipeline opportunities. The decision to discontinue JANX008 is program-specific and does not impact the Company's broader TRACTr platfor
- ANALYSTJanux Therapeutics downgraded by Barclays with a new price targetBarclays downgraded Janux Therapeutics from Overweight to Underweight and set a new price target of $14.00
- PRJanux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014-JANX014 expands Janux's PSMA tumor-activated T cell engager portfolio -JANX007 is the Company's lead prostate cancer program and primary development priority -JANX013, a PSMA-TRACIr CD28 co-stimulatory program, planned to enter the clinic in 2H2026 Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial of JANX014 in patients with metastatic castration-resistant prostate cancer (mCRPC). JANX014 is a double-masked, prostate-specific membrane antigen (PSMA) directed T cell engager (TCE) designed to leverage Janux's tu
JANX FAQ
6 questionsWhere does JANX stock trade?
Janux Therapeutics Inc. (JANX) is listed on NASDAQ.What sector and industry is JANX in?
Janux Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Janux Therapeutics Inc. go public?
Janux Therapeutics Inc. (JANX) completed its IPO in 2021.What are analysts saying about JANX?
Janux Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Underweight with a $1400.00 price target on 2026-04-20. Recent price targets range from $1400.00 to $4700.00.What companies are similar to JANX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare JANX side-by-side with any of them on Quantisnow.How can I track JANX on Quantisnow?
Quantisnow aggregates Janux Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow JANX to receive live email and push alerts on every new disclosure.